Trials / Completed
CompletedNCT00406211
Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine
Follow-up to Evaluate the the Immunogenicity & Safety of GSK Biologicals' MMRV Vaccine Given as a Two-dose Schedule in the Second Year of Life, as Compared to Separate Administration of GSK Biologicals' Priorix® & Varilrix®.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 398 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Months – 18 Months
- Healthy volunteers
- Accepted
Summary
Follow-up to evaluate the immunogenicity and safety of three production lots of GSK Biologicals' MMRV vaccine given as a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' measles-mumps-rubella (MMR) vaccine (Priorix®) and varicella vaccine (Varilrix®) in Germany \& Austria. Blood samples were collected at three time points during the follow-up period (Year 1, 2 \& 3). No new subjects will be enrolled in these follow-up phases of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MMRV | |
| BIOLOGICAL | MMR (Priorix®) | |
| BIOLOGICAL | Varicella (Varilrix®) |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2004-12-01
- Completion
- 2004-12-01
- First posted
- 2006-12-04
- Last updated
- 2016-09-15
Locations
41 sites across 2 countries: Austria, Germany
Source: ClinicalTrials.gov record NCT00406211. Inclusion in this directory is not an endorsement.